Table 1.
Clinical, echocardiographic, and cardiac magnetic resonance imaging characteristics for all groups.
| Parameters | Control group (n = 39) | CA | P1 | CArEF (n = 29) | CApEF (n = 10) | P2 |
|---|---|---|---|---|---|---|
| Clinical characteristics | ||||||
| Age (years) | 49.15 ± 13.86 | 54.69 ± 12.25 | 0.061 | 53.55 ± 12.31 | 58.40 ± 11.92 | 0.286 |
| Gender, Male [n (%)] | 23 (58.97%) | 30 (76.92%) | 0.072 | 22 (75.86%) | 8 (80.00%) | 0.581 |
| Hemodynamic data | ||||||
| Heart Rate | 69.00 ± 12.26 | 80.77 ± 14.60 | 0.001 | 82.21 ± 15.61 | 76.60 ± 10.76 | 0.301 |
| Echocardiology | ||||||
| LAD (mm) | 34.38 ± 4.18 | 45.00 ± 7.25 | 0.000 | 44.93 ± 8.11 | 45.22 ± 3.80 | 0.918 |
| LVEDD (mm) | 45.73 ± 4.75 | 45.05 ± 9.04 | 0.701 | 45.82 ± 9.47 | 42.67 ± 7.52 | 0.370 |
| LVESD (mm) | 29.23 ± 2.83 | 32.97 ± 7.99 | 0.012 | 34.36 ± 8.28 | 28.67 ± 5.32 | 0.062 |
| IVST (mm) | 8.96 ± 1.40 | 14.27 ± 2.22 | 0.000 | 14.04 ± 2.32 | 15.00 ± 1.80 | 0.263 |
| PWT (mm) | 8.58 ± 1.14 | 13.35 ± 2.52 | 0.000 | 13.07 ± 2.51 | 14.22 ± 2.49 | 0.238 |
| PASP (mmHg) | 31.54 ± 3.61 | 40.89 ± 10.98 | 0.000 | 42.36 ± 11.90 | 36.33 ± 5.77 | 0.155 |
| CMR parameters | ||||||
| LVEDVi (ml/m2) | 73.93 ± 15.78 | 80.41 ± 32.19 | 0.268 | 84.22 ± 34.68 | 69.35 ± 21.25 | 0.212 |
| LVESVi (ml/m2) | 30.89 ± 9.16 | 52.29 ± 28.78 | 0.000 | 58.19 ± 30.70 | 35.16 ± 11.23 | 0.002 |
| SVi (ml/m2) | 43.08 ± 8.37 | 28.12 ± 9.63 | 0.000 | 26.03 ± 7.81 | 34.19 ± 12.12 | 0.019 |
| LVEF (%) | 59.68 ± 6.38 | 37.48 ± 10.55 | 0.000 | 32.87 ± 7.46 | 50.87 ± 5.85 | 0.000 |
CA, cardiac amyloidosis; LAD, left atrial dimension; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; IVST, interventricular septum thickness; PWT, left ventricular post wall thickness; PASP, pulmonary arterial systolic pressure; LVEDVi, body surface area indexed left ventricular end-diastolic volume; LVESVi, body surface area indexed left ventricular end-systolic volume; Svi, body surface area indexed systolic volume; LVEF, left ventricular ejection fraction.
P1: CA vs. control group; P2: CArEF vs. CApEF.